ArticleiScience2026
Fabrication of RADA32/Ngf_EE/MSCs composite hydrogel and its protective mechanism against radiation-induced ototoxicity.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is a cornerstone in head and neck tumor treatment, but 47.4% of treated patients experience radiation-induced hearing loss despite precise techniques. To address inner ear barriers and drug delivery limits, we developed an injectable peptide self-assembling hydrogel-RNM-composed of RADA32, Ngf_EE, and mesenchymal stem cells (MSCs). This system forms stable nanofibrous networks, is efficiently endocytosed by hair cells, and enhances MSC activity. RNM significantly reduces radiation-induced reactive oxygen species (ROS) and inflammation, thereby decreasing cell apoptosis and DNA damage. In irradiated mice, minimally invasive intratympanic injection of RNM partially repaired cochlear outer hair cell and spiral ganglion structural damage and restored auditory function. This protection is mediated by inhibiting the NF-κB signaling pathway and reversing M1 polarization of cochlear macrophages. Additionally, intratympanic delivery showed good biosafety. In conclusion, RNM exerts a dual mechanism of immunomodulation and enhanced inner ear cell viability, effectively protecting against radiation-induced inner ear injury, with promising clinical translation potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.